Form 4: MAIA Biotechnology Director Acquires Stock Options

Director Stan Smith reports acquisition of stock options in MAIA Biotechnology, Inc.

Summary

• Stan Smith, a director of MAIA Biotechnology, Inc., filed a Form 4 on April 8, 2025, reporting a transaction.
• On April 4, 2025, Smith acquired 24,800 stock options with an exercise price of $1.50.
• These options vest immediately and are exercisable from the grant date, expiring on April 4, 2035.
• The options are granted under the company's 2021 Equity Incentive Plan.
• Smith also indirectly owns 24,800 shares of common stock through The Stan V. Smith Trust Dated 1993.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard disclosure of stock option acquisition. The director's acquisition could be interpreted as a slightly positive signal, but it's not definitively bullish.

Positives

• The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.

Stakeholder Impact

• The acquisition of stock options by a director may have a minor positive impact on shareholder sentiment.

Key Dates

Keywords

MAIA Biotechnology, Stock Options, Form 4, Director, Beneficial Ownership, Equity Incentive Plan